SG11201903801YA - Pyridone compound as c-met inhibitor - Google Patents
Pyridone compound as c-met inhibitorInfo
- Publication number
- SG11201903801YA SG11201903801YA SG11201903801YA SG11201903801YA SG11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA SG 11201903801Y A SG11201903801Y A SG 11201903801YA
- Authority
- SG
- Singapore
- Prior art keywords
- met inhibitor
- pyridone compound
- met
- pyridone
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
PyridoneCompound as C-MET Inhibitor Disclosed in the present invention is a type of pyridone specifically disclosed is a compound as shown in formula (I) thereof. compounds as c-met or a pharmaceutically acceptable inhibitors, and salt R 0 0 (I) A' N N <-.- R 2 N.„.... - - --.. 0 -..„,..N., 39
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610954377 | 2016-10-27 | ||
| PCT/CN2017/107964 WO2018077227A1 (en) | 2016-10-27 | 2017-10-27 | Pyridone compound as c-met inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903801YA true SG11201903801YA (en) | 2019-05-30 |
Family
ID=62024383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903801YA SG11201903801YA (en) | 2016-10-27 | 2017-10-27 | Pyridone compound as c-met inhibitor |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10501443B2 (en) |
| EP (1) | EP3533787B1 (en) |
| JP (1) | JP6719679B2 (en) |
| KR (1) | KR102070748B1 (en) |
| CN (1) | CN109311812B (en) |
| AU (1) | AU2017348810B2 (en) |
| BR (1) | BR112019008415B1 (en) |
| CA (1) | CA3041164C (en) |
| CO (1) | CO2019005165A2 (en) |
| DK (1) | DK3533787T3 (en) |
| EA (1) | EA038108B1 (en) |
| ES (1) | ES2835301T3 (en) |
| HR (1) | HRP20201985T1 (en) |
| HU (1) | HUE051734T2 (en) |
| IL (1) | IL266126B (en) |
| LT (1) | LT3533787T (en) |
| MX (1) | MX2019004626A (en) |
| MY (1) | MY189557A (en) |
| PE (1) | PE20190912A1 (en) |
| PH (1) | PH12019500875A1 (en) |
| PL (1) | PL3533787T3 (en) |
| PT (1) | PT3533787T (en) |
| RS (1) | RS61126B1 (en) |
| SG (1) | SG11201903801YA (en) |
| SI (1) | SI3533787T1 (en) |
| UA (1) | UA122737C2 (en) |
| WO (1) | WO2018077227A1 (en) |
| ZA (1) | ZA201903074B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102374933B1 (en) * | 2018-04-26 | 2022-03-15 | 푸젠 코선터 파마슈티컬 컴퍼니 리미티드 | Crystalline form of c-Met inhibitor, salt form thereof and preparation method |
| JP7214879B2 (en) * | 2019-02-01 | 2023-01-30 | メッドシャイン ディスカバリー インコーポレイテッド | Tricyclyl compounds containing pyrimidinyls as c-Met inhibitors |
| WO2022063869A2 (en) | 2020-09-24 | 2022-03-31 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| EP4346829A1 (en) | 2021-06-04 | 2024-04-10 | Merck Patent GmbH | Compounds for the treatment of glioblastoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002002519A2 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | THROMBIN OR FACTOR Xa INHIBITORS |
| US7732456B2 (en) | 2004-03-05 | 2010-06-08 | Banyu Pharmaceutical Co., Ltd. | Pyridone derivative |
| US8314087B2 (en) * | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| DE102007032507A1 (en) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | pyridazinone derivatives |
| DE102008062826A1 (en) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | pyridazinone derivatives |
| EP2768826A1 (en) | 2011-10-17 | 2014-08-27 | Bayer Intellectual Property GmbH | Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors |
| KR20140138984A (en) * | 2012-03-19 | 2014-12-04 | 메르크 파텐트 게엠베하 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds |
| RU2684407C2 (en) * | 2012-10-11 | 2019-04-09 | Мерк Патент Гмбх | Combination of 6-oxo-1,6-dihydro-pyridazine derivative having anticolic activity, with mek inhibitor |
| BR112017010232A2 (en) * | 2014-12-11 | 2018-01-02 | Merck Patent Gmbh | COMBINATION OF A 6-OXO-1,6-DI-HYDRO-PYRIDAZINE DERIVATIVE HAVING ANTICANCER ACTIVITY WITH A QUINAZOLIN DERIVATIVE |
-
2017
- 2017-10-27 HU HUE17864813A patent/HUE051734T2/en unknown
- 2017-10-27 LT LTEP17864813.5T patent/LT3533787T/en unknown
- 2017-10-27 SG SG11201903801YA patent/SG11201903801YA/en unknown
- 2017-10-27 UA UAA201904417A patent/UA122737C2/en unknown
- 2017-10-27 US US16/343,387 patent/US10501443B2/en active Active
- 2017-10-27 PL PL17864813T patent/PL3533787T3/en unknown
- 2017-10-27 WO PCT/CN2017/107964 patent/WO2018077227A1/en unknown
- 2017-10-27 RS RS20201448A patent/RS61126B1/en unknown
- 2017-10-27 SI SI201730558T patent/SI3533787T1/en unknown
- 2017-10-27 DK DK17864813.5T patent/DK3533787T3/en active
- 2017-10-27 MX MX2019004626A patent/MX2019004626A/en active IP Right Grant
- 2017-10-27 EP EP17864813.5A patent/EP3533787B1/en active Active
- 2017-10-27 BR BR112019008415-0A patent/BR112019008415B1/en active IP Right Grant
- 2017-10-27 CA CA3041164A patent/CA3041164C/en active Active
- 2017-10-27 CN CN201780036464.XA patent/CN109311812B/en active Active
- 2017-10-27 EA EA201990952A patent/EA038108B1/en unknown
- 2017-10-27 AU AU2017348810A patent/AU2017348810B2/en active Active
- 2017-10-27 ES ES17864813T patent/ES2835301T3/en active Active
- 2017-10-27 JP JP2019540379A patent/JP6719679B2/en active Active
- 2017-10-27 KR KR1020197014236A patent/KR102070748B1/en active IP Right Grant
- 2017-10-27 MY MYPI2019002142A patent/MY189557A/en unknown
- 2017-10-27 PE PE2019000855A patent/PE20190912A1/en unknown
- 2017-10-27 PT PT178648135T patent/PT3533787T/en unknown
-
2019
- 2019-04-18 IL IL266126A patent/IL266126B/en active IP Right Grant
- 2019-04-22 PH PH12019500875A patent/PH12019500875A1/en unknown
- 2019-05-16 ZA ZA2019/03074A patent/ZA201903074B/en unknown
- 2019-05-21 CO CONC2019/0005165A patent/CO2019005165A2/en unknown
-
2020
- 2020-12-10 HR HRP20201985TT patent/HRP20201985T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014864A (en) | Bisamide sarcomere activating compounds and uses thereof. | |
| NZ729005A (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| PH12016500467A1 (en) | Aminoheteroarlyl benzamides as kinase inhibitors | |
| MX2021014531A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith. | |
| MX2014012454A (en) | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation. | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
| MA40059A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2016000675A (en) | Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof. | |
| PH12019500875A1 (en) | Pyridone compound as c-met inhibitor | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| EA201991253A1 (en) | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | |
| JO3318B1 (en) | Bace inhibitors | |
| MX2022006783A (en) | New methylquinazolinone derivatives. | |
| PH12016502246B1 (en) | Carboxamide derivatives | |
| MX2018014813A (en) | Antibacterial compositions. | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| MX368496B (en) | Analogues of 4h-pyrazolo[1,5-a]benzimidazole compound as parp inhibitors. | |
| WO2018039077A8 (en) | Therapeutic compounds | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor |